Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Japan's Ministry of Health, Labour and Welfare has accepted GSK's new drug application for Blenrep in combination with other drugs for treating relapsed or refractory multiple myeloma.
September 17, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's new drug application for Blenrep in combination with other drugs for multiple myeloma has been accepted for review by Japan's Ministry of Health, potentially expanding its market in Japan.
The acceptance of GSK's drug application by Japan's Ministry of Health is a positive regulatory step, indicating potential future approval and market expansion in Japan. This could lead to increased revenues from the Japanese market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90